Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN M HEMPHILL

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology with Special Qualifications in Child Neurology

NPI
1285672329
CMS profile
194509
Location
SAVANNAH, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$405,069.95

574 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Eisai Inc. $105,552.72 104
ARGENX US, INC. $63,626.96 64
EMD Serono, Inc. $52,301.67 49
Alexion Pharmaceuticals, Inc. $50,581.05 48
Amgen Inc. $48,555.92 56
TG Therapeutics, Inc. $26,034.96 25
ABBVIE INC. $20,532.55 44
E.R. Squibb & Sons, L.L.C. $10,450.19 9
UCB, Inc. $10,381.58 24
Genentech USA, Inc. $7,153.56 12
Vanda Pharmaceuticals Inc. $5,331.35 4
Janssen Scientific Affairs, LLC $1,362.50 1
Celgene Corporation $341.52 4
Axsome Therapeutics, Inc. $262.75 5
PFIZER INC. $246.83 13
Biogen, Inc. $243.46 11
Lundbeck LLC $242.63 13
Mallinckrodt Hospital Products Inc. $176.36 7
SK Life Science, Inc. $162.30 7
Neurocrine Biosciences, Inc. $146.50 7
Teva Pharmaceuticals USA, Inc. $143.68 8
Neurelis, Inc. $141.94 7
CATALYST PHARMACEUTICALS, INC. $124.41 7
GENZYME CORPORATION $110.27 1
CSL Behring $81.74 3
Ipsen Biopharmaceuticals, Inc $76.20 4
JAZZ PHARMACEUTICALS INC. $76.17 5
Sumitomo Pharma America, Inc. $72.90 4
ACADIA Pharmaceuticals Inc $52.75 3
AstraZeneca Pharmaceuticals LP $51.99 3
Otsuka America Pharmaceutical, Inc. $50.85 3
Grifols USA, LLC $45.47 2
LivaNova USA, Inc. $44.99 2
SCILEX PHARMACEUTICALS INC. $37.00 2
Lilly USA, LLC $30.69 1
ANI Pharmaceuticals, Inc. $30.42 1
HARMONY BIOSCIENCES LLC $24.36 1
REVANCE THERAPEUTICS, INC. $21.83 1
Alnylam Pharmaceuticals Inc. $20.87 1
Takeda Pharmaceuticals U.S.A., Inc. $20.83 1
MITSUBISHI TANABE PHARMA AMERICA, INC. $20.64 1
Averitas Pharma Inc. $19.35 1
Merz Pharmaceuticals, LLC $19.15 1
BANNER LIFE SCIENCES, LLC $18.55 1
Boston Scientific Corporation $16.09 1
Marinus Pharmaceuticals, Inc. $15.73 1
InSightec,Inc $13.72 1

Page 9 of 12; records 401–450 of 574 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN M HEMPHILL

NPI 1285672329 · CMS profile ID 194509

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology with Special Qualifications in Child Neurology

SAVANNAH, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 9 of 12; records 401–450 of 574 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285672329?year=2024&recipient=provider&page=9#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN M HEMPHILL, NPI 1285672329, CMS profile ID 194509. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 9 of 12; records 401–450 of 574 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285672329?year=2024&recipient=provider&page=9#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JOHN M HEMPHILL, NPI 1285672329, CMS profile ID 194509. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 9 of 12; records 401–450 of 574 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285672329?year=2024&recipient=provider&page=9#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JOHN M HEMPHILL, NPI 1285672329, CMS profile ID 194509, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 9 of 12; records 401–450 of 574 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1285672329?year=2024&recipient=provider&page=9#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

574 matching records · $405,069.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 574 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 401–450 of 574.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Otsuka America Pharmaceutical, Inc. $14.3605/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118907579 CMS
Eisai Inc. $121.8805/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110753666 CMS
Eisai Inc. $1,462.5005/09/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110753676 CMS
Eisai Inc. $3,510.0005/09/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110753712 CMS
Eisai Inc. $1,620.0005/09/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155794814 CMS
Neurelis, Inc. $18.5805/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145643314 CMS
Celgene Corporation $13.9005/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101105456 CMS
E.R. Squibb & Sons, L.L.C. $121.9805/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101309347 CMS
Lundbeck LLC $13.3105/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145924452 CMS
SK Life Science, Inc. $26.6105/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154122845 CMS
ABBVIE INC. $19.9905/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103903240 CMS
EMD Serono, Inc. $2,083.0005/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120214422 CMS
EMD Serono, Inc. $6,843.0005/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120214580 CMS
CSL Behring $22.2704/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134654249 CMS
Genentech USA, Inc. $24.1504/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133035000 CMS
Teva Pharmaceuticals USA, Inc. $25.3404/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151541317 CMS
TG Therapeutics, Inc. $4,185.0004/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136869222 CMS
TG Therapeutics, Inc. $159.2404/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136869228 CMS
TG Therapeutics, Inc. $632.2004/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136869232 CMS
TG Therapeutics, Inc. $430.6004/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136869234 CMS
Otsuka America Pharmaceutical, Inc. $18.6904/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118907577 CMS
PFIZER INC. $23.1004/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131402573 CMS
PFIZER INC. $4.3604/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131661500 CMS
Mallinckrodt Hospital Products Inc. $26.6504/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145082298 CMS
UCB, Inc. $20.1104/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143337422 CMS
Biogen, Inc. $24.5804/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104844110 CMS
TG Therapeutics, Inc. $34.2504/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136869170 CMS
ABBVIE INC. $24.1804/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103903238 CMS
ABBVIE INC. $139.2704/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103903236 CMS
EMD Serono, Inc. $105.5204/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120239194 CMS
Amgen Inc. $111.7404/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111597600 CMS
EMD Serono, Inc. $1,751.4504/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120212020 CMS
EMD Serono, Inc. $273.7304/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120214052 CMS
Alexion Pharmaceuticals, Inc. $1,180.0004/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093980353 CMS
Lundbeck LLC $18.5604/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145924450 CMS
SK Life Science, Inc. $25.4404/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154122843 CMS
TG Therapeutics, Inc. $22.7804/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136869174 CMS
UCB, Inc. $23.0404/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143337414 CMS
UCB, Inc. $1,434.9404/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143337418 CMS
ARGENX US, INC. $2,500.0004/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142112945 CMS
EMD Serono, Inc. $4,463.0004/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120214014 CMS
EMD Serono, Inc. $4,463.0004/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120214016 CMS
UCB, Inc. $40.0004/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143337409 CMS
EMD Serono, Inc. $21.4803/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120239196 CMS
Eisai Inc. $3,510.0003/28/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110753668 CMS
Eisai Inc. $585.0003/28/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110753672 CMS
Eisai Inc. $1,462.5003/28/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110753700 CMS
Eisai Inc. $112.2403/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110753708 CMS
Eisai Inc. $1,462.5003/28/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110753710 CMS
Eisai Inc. $24.2903/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110753724 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $325,932.61 707
PY2020 $147,867.73 403
PY2021 $223,080.08 413
PY2022 $267,103.38 499
PY2023 $260,467.60 454
PY2024 $405,069.95 574
PY2025 $393,996.28 514

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $197,381.32 62
PY2024 Principal investigator $454,760.68 110
PY2023 Recipient $17,410.30 3
PY2023 Principal investigator $322,019.08 88
PY2022 Recipient $28,528.00 3
PY2022 Principal investigator $383,448.81 38
PY2021 Recipient $100.00 1
PY2021 Principal investigator $341,432.65 50
PY2020 Principal investigator $699,854.25 100
PY2019 Recipient $9,074.88 9
PY2019 Principal investigator $513,557.89 67

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $22,600.00 11/30/2025 Non-covered Recipient Entity
Savannah Neurology Specialists, PC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200803
Principal investigator 1 GENZYME CORPORATION $17,500.00 11/17/2025 Non-covered Recipient Entity
Savannah Neurology Specialists
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226127050
Principal investigator 1 GENZYME CORPORATION $16,800.00 11/17/2025 Non-covered Recipient Entity
Savannah Neurology Specialists
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226127054
Principal investigator 1 TG Therapeutics, Inc. $14,900.00 11/01/2025 Non-covered Recipient Entity
Savannah Neurology Specialists, PC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200801
Principal investigator 1 TG Therapeutics, Inc. $9,900.00 09/30/2025 Non-covered Recipient Entity
Savannah Neurology Specialists, PC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200797
Principal investigator 1 TG Therapeutics, Inc. $17,200.00 08/31/2025 Non-covered Recipient Entity
Savannah Neurology Specialists, PC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200795
Principal investigator 1 Ipsen Innovation $315.00 08/28/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296135
Principal investigator 1 Ipsen Innovation $2,373.00 08/28/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296137
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653164
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653170
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653175
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653179
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653183
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653187
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653191
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653195
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653198
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653202
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653206
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653210
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653214
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653220
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653224
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653230
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653234
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653238
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653241
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653245
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653249
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653253
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653257
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653262
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653265
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653269
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653273
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653276
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653279
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653283
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653287
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653291
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653298
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653302
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653306
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653310
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653314
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653317
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653321
Principal investigator 1 Roche Products Limited $77.10 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653323
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653326
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653329
Principal investigator 1 Roche Products Limited $257.00 08/25/2025 Non-covered Recipient Entity
SAVANNAH NEUROLOGY SPECIALISTS PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653332
Principal investigator 1 Roche Products Limited $257.00 08/21/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211624570
Principal investigator 1 Roche Products Limited $257.00 08/21/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211624574
Principal investigator 1 Roche Products Limited $257.00 08/21/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211624579
Principal investigator 1 Roche Products Limited $128.50 08/21/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211624583
Principal investigator 1 TG Therapeutics, Inc. $15,700.00 07/31/2025 Non-covered Recipient Entity
Savannah Neurology Specialists, PC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200793
Principal investigator 1 TG Therapeutics, Inc. $10,600.00 06/01/2025 Non-covered Recipient Entity
Savannah Neurology Specialists, PC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200783
Principal investigator 1 GENZYME CORPORATION $17,250.00 04/14/2025 Non-covered Recipient Entity
Velocity Clinical Research, Savannah
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226148817
Principal investigator 1 Genentech, Inc. $5,000.00 02/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Satralizumab in MOG AD No dispute reported 06/30/2026 1211682106
Principal investigator 1 Novartis Pharmaceuticals Corporation $68.40 01/31/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190307457
Principal investigator 1 Roche Products Limited $257.00 01/09/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211624566
Principal investigator 1 Novartis Pharmaceuticals Corporation $35,147.32 01/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190307459